Oceanside Pharmaceuticals Announces Launch of Librax(R) AG.
ALISO VIEJO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Oceanside Pharmaceuticals, part of Valeant Pharmaceuticals International , today announced that it has now launched chlordiazepoxide hydrochloride and clidinium bromide, an authorized generic (AG) version of LibraxA'. Oceanside has received its first orders and expects to be a significant player in the LibraxA' generic market.
"Valeant's Oceanside unit has become an important division of our U.S. business with its successful launch and distribution of 5% fluorouracil, Valeant's authorized generic of EfudexA'," stated J. Michael Pearson, chairman and chief executive officer. "Oceanside currently maintains a 55% market share of its EfudexA' AG and plans to retain this leadership position in the future. With the industry experience we have had with EfudexA' AG, we believe that we can successfully grow a strong market position with the launch of LibraxA' AG."
Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at http://www.valeant.com/.
This press release may contain forward-looking statements, including, but not limited to, statements regarding Oceanside's launch and growth of Librax AG and Oceanside's strong leadership position with Efudex AG. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the U.S. Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.
Contact: Laurie W. Little Valeant Pharmaceuticals 949-461-6002 email@example.com
CONTACT: Laurie W. Little of Valeant Pharmaceuticals, +1-949-461-6002, firstname.lastname@example.org
Web Site: http://www.valeant.com/
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 23, 2009|
|Previous Article:||Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference.|
|Next Article:||Diedrich Coffee Evaluating Revised Offer From Peet's Coffee & Tea.|